โ Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (464) ๐ ๏ธ Industry Q&A (98) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
Date | Press release |
---|---|
2025-05-23 08:30:00 | Ascent-03: Trodelvyยฎ Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement In Progression Free Survival In Patients With First-line Metastatic Triple-negative Breast Cancer Who Are Not Candidates For Checkpoint Inhibitors Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) today announced positive topline results from the phase 3 ascent-03 study of trodelvyยฎ (sacituzumab govitecan-hziy). the study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (pfs) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mtnbc) who are not candidates for pd-1/pd-l1 inhibitor. |
2025-05-15 16:15:00 | Gilead And Kite Announce Presentation Of Transformative Data In 1l Metastatic Triple-negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational Car T-cell Therapy Targeting Brain Cancer At 2025 Asco And Eha Foster city, calif. & santa monica, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) will present more than 20 abstracts across both gilead and kite at the upcoming 2025 american society of clinical oncology (asco) annual meeting may 30 โ june 3 and the 2025 european hematology association (eha) annual congress june 12 โ 15. the studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multi. |
2025-05-07 02:30:00 | Final Data From The Phase 3 Myr301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment Foster city, calif.--(business wire)--gilead sciences inc. (nasdaq: gild) today announced final results from the pivotal phase 3 myr301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (hdv) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable hdv rna at end of treatment (eot). in participants who sustained u. |
2025-05-07 02:15:00 | Gileadโs Livdelziยฎ (seladelpar) Demonstrated Consistent Efficacy And Safety Regardless Of Prior Treatment History In New Data Presented At Easl 2025 Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) today announced new data from multiple analyses which reinforce that livdelziยฎ (seladelpar), known as lyvdelziยฎ in the european union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (pbc) and also provides sustained biochemical response in adults with pbc regardless of prior treatment history. another analysis provides evidence supporting that livdelzi delivered clinically and. |
2025-04-29 16:05:00 | Gilead Sciences To Present At Upcoming Investor Conferences Foster city, calif.--(business wire)-- #gild--gilead sciences, inc. (nasdaq: gild) announced today that its executives will be speaking at the following investor conferences: bofa securities health care conference on tuesday, may 13 at 11:20 am pacific time rbc capital markets global healthcare conference on wednesday, may 21 at 11:30 am eastern time bernstein annual strategic decisions conference on thursday, may 29 at 2:30 pm eastern time jefferies global healthcare conference on wednesday, june 4 at. |
2025-04-29 08:30:00 |
|
2025-04-24 16:02:00 |
|
2025-04-10 16:05:00 |
|
2025-03-12 08:30:00 |
|
2025-03-11 13:37:00 |
|
2025-02-24 08:30:00 |
|
2025-02-20 16:30:00 |
|
2025-02-19 16:05:00 |
|
2025-02-18 08:30:00 |
|
2025-02-11 16:05:00 |
|

๐ฐ Browse additional press releases for Gilead Sciences!
Sign up for free or log in๐ Free download! "The Checklist Value Investor โ A Smarter Way to Pick Stocks"